Addition of Azathioprine in IBD Patients With Immunogenic Failure
Status:
Unknown status
Trial end date:
2020-06-10
Target enrollment:
Participant gender:
Summary
Loss of response under anti-TNF is frequent. 20% of patients with clinical relapse present an
immune mediated pharmacokinetic failure. In the last AGA recommendations, switch to another
anti-TNF drug is suggested with no indication of immunosuppressive agent. In a recent study,
70% of patients with an immunogenic failure to a first anti-TNF agent developed a new
immunogenic failure to the second anti-TNF drug using alone.